Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy

Table 1

Predictive value for recurrence in cancer-related factors and molecules.

Variable	Patients		Agent	value for recurrence		Year/reference
		Background		Univariate	Multivariate
Ki-67	92	Tis, T1G3	BCG	0.015		2009/[16]
	129	T1G3	MMC	0.517		2010/[17]
	72	Ta, T1	MMC/epirubicin	0.011	0.044	2012/[18]
	61	T1G3	BCG	0.677		2013/[19]
P53	53	Tis, Ta, T1	BCG	0.741		2007/[20]
	27	T1G3	BCG	0.92		2009/[21]
	129	T1G3	MMC	0.452		2010/[17]
	61	T1G3	BCG	0.794		2013/[19]
	134	T1 HG	BCG	0.830		2015/[22]
pRb	53	Tis, Ta, T1	BCG	0.580		2007/[20]
	27	T1G3	BCG	0.037		2009/[21]
	61	T1G3	BCG	0.951		2013/[19]
Survivin	74	Tis, Ta, T1	BCG/MMC	0.003	0.02	2007/[23]
	78	Ta and T1	BCG	0.009		2012/[24]
	78	Ta and T1	BCG	0.043		2012/[24]
p27	61	T1G3	BCG	0.822		2013/[19]
p63	134	T1 HG	BCG	0.129		2015/[22]
ΔNp63	134	T1 HG	BCG	<0.001		2015/[22]
PTEN	61	T1G3	BCG	0.306		2013/[19]
FGFR3	61	T1G3	BCG	0.355		2013/[19]
Ezrin	92	Tis, T1G3	BCG	0.041		2009/[16]
CD9	61	T1G3	BCG	0.760		2013/[19]
MVD	26	Ta, T1	BCG	<0.0001	0.0011	2011/[25]
AT1R	26	Ta, T1	BCG	<0.0001	0.0012	2011/[25]
VEGF	72	Ta, T1	MMC/epirubicin	0.010	0.036	2015/[26]

BCG: Bacillus Calmette-Guérin; MMC: mitomycin C; Rb: retinoblastoma; PTEN: phosphatase and tensin homolog; FGFR: fibroblast growth factor receptor; MVD: microvessel density; AT1R: Angiotensin II Type I Receptor.
One hundred thirty-one (97.8%) patients were treated with adjuvant intravesical BCG therapy.
Among 74 patients, 54 (73.0%) were treated with intravesical BCG or MMC therapy.
Hazard ratio and 95% confidential interval were 0.383 and 0.193–0.961, respectively. value was not shown.